Irina Heid, Corinna Münch, Sinan Karakaya, Smiths S Lueong, Alina M Winkelkotte, Sven T Liffers, Laura Godfrey, Phyllis F Y Cheung, Konstantinos Savvatakis, Geoffrey J Topping, Florian Englert, Lukas Kritzner, Martin Grashei, Andrea Tannapfel, Richard Viebahn, Heiner Wolters, Waldemar Uhl, Deepak Vangala, Esther M M Smeets, Erik H J G Aarntzen, Daniel Rauh, Wilko Weichert, Jörg D Hoheisel, Stephan A Hahn, Franz Schilling, Rickmer Braren, Marija Trajkovic-Arsic, Jens T Siveke
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) lacks effective treatment options beyond chemotherapy. Although molecular subtypes such as classical and QM (quasi-mesenchymal)/basal-like with transcriptome-based distinct signatures have been identified, deduced therapeutic strategies and targets remain elusive. Gene expression data show enrichment of glycolytic genes in the more aggressive and therapy-resistant QM subtype. However, whether the glycolytic transcripts are translated into functional glycolysis that could further be explored for metabolic targeting in QM subtype is still not known...
December 9, 2022: Cancer & Metabolism